TY - JOUR
T1 - Accurate detection of low-level mosaic mutations in pediatric acute lymphoblastic leukemia using single molecule tagging and deep-sequencing
AU - Yu, Jiangyan
AU - Antić, Željko
AU - van Reijmersdal, Simon V
AU - Hoischen, Alexander
AU - Sonneveld, Edwin
AU - Waanders, Esmé
AU - Kuiper, Roland P
N1 - Funding Information:
This work was supported by grants from the Dutch Cancer Society (KWF; KUN2009-4298 to RPK, KUN2012-5366 to EW), Stichting Kinderen Kankervrij (KiKa 150 to RPK and AH), and the China Scholarship Council (CSC201304910347 to JY).
Publisher Copyright:
© 2017, © 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/7/3
Y1 - 2018/7/3
N2 - Pathogenic mutations in relapse-associated genes in pediatric acute lymphoblastic leukemia may improve risk stratification when detected at subclonal levels at primary diagnosis. However, to detect subclonal mutations upfront, a deep-sequencing approach with high specificity and sensitivity is required. Here, we performed a proof-of-principle study to detect low-level mosaic RAS pathway mutations by deep sequencing using random tagging-based single molecule Molecular Inversion Probes (smMIPs). The smMIP-based approach could sensitively detect variants with allele frequency as low as 0.4%, which could all be confirmed by other techniques. In comparison, with standard deep-sequencing techniques we reached a detection threshold of only 2.5%, which hampered detection of seven low-level mosaic mutations representing 24% of all detected mutations. We conclude that smMIP-based deep-sequencing outperforms standard deep-sequencing techniques by showing lower background noise and high specificity, and is the preferred technology for detecting mutations upfront, particularly in genes in which mutations show limited clustering in hotspots.
AB - Pathogenic mutations in relapse-associated genes in pediatric acute lymphoblastic leukemia may improve risk stratification when detected at subclonal levels at primary diagnosis. However, to detect subclonal mutations upfront, a deep-sequencing approach with high specificity and sensitivity is required. Here, we performed a proof-of-principle study to detect low-level mosaic RAS pathway mutations by deep sequencing using random tagging-based single molecule Molecular Inversion Probes (smMIPs). The smMIP-based approach could sensitively detect variants with allele frequency as low as 0.4%, which could all be confirmed by other techniques. In comparison, with standard deep-sequencing techniques we reached a detection threshold of only 2.5%, which hampered detection of seven low-level mosaic mutations representing 24% of all detected mutations. We conclude that smMIP-based deep-sequencing outperforms standard deep-sequencing techniques by showing lower background noise and high specificity, and is the preferred technology for detecting mutations upfront, particularly in genes in which mutations show limited clustering in hotspots.
KW - Alleles
KW - Biomarkers, Tumor
KW - Child
KW - Chromosome Inversion
KW - DNA Mutational Analysis/methods
KW - DNA Probes
KW - High-Throughput Nucleotide Sequencing
KW - Humans
KW - Mosaicism
KW - Mutation
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis
KW - Single Molecule Imaging/methods
KW - low-level mosaic mutations
KW - single molecule Molecular Inversion Probes
KW - molecular tagging
KW - Acute lymphoblastic leukemia
KW - deep sequencing
UR - http://www.scopus.com/inward/record.url?scp=85031900017&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1390232
DO - 10.1080/10428194.2017.1390232
M3 - Article
C2 - 29058513
SN - 1026-8022
VL - 59
SP - 1690
EP - 1699
JO - Leukemia & lymphoma
JF - Leukemia & lymphoma
IS - 7
ER -